Pre-screening Study to Identify Adult Participants with Classic Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency Who May Be Eligible for Treatment in the CAH-301 Trial with BBP-631, an Adeno-associated Virus (AAV) Serotype 5-Based Recombinant Vector Encoding the Human CYP21A2 Gene
Latest Information Update: 26 Sep 2024
At a glance
- Drugs BBP-631 (Primary)
- Indications Congenital adrenal hyperplasia
- Focus Therapeutic Use
- Sponsors Adrenas Therapeutics
- 19 Sep 2024 Status changed from recruiting to completed.
- 09 Jul 2024 Planned End Date changed from 1 Jun 2024 to 1 Dec 2024.
- 09 Jul 2024 Planned primary completion date changed from 1 Jun 2024 to 1 Dec 2024.